Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
17/09/2025
Chunzhong Technology hits the daily limit for two consecutive days, with a total increase of 21.0% in two days.
Latest
1 m ago
Scale AI opens platform to US Department of Defense with $100 million contract.
2 m ago
ASEAN leaders: The East Expo will promote inclusive and sustainable growth between ASEAN and China.
3 m ago
Rongchang Biotech: Currently, the overseas clinical trials of RC48 are progressing as planned.
3 m ago
Rongchang Bio (688331.SH) stated at the performance briefing that the company has reached a global exclusive license agreement with Seattle Genetics, Inc. (now acquired by Pfizer Inc.) in 2021. The company has granted the global development and commercialization rights of vedolizumab (code: RC48) in the Rongchang Bio region (i.e. all Asian regions except Japan and Singapore) outside of its territory. Currently, Pfizer is progressing overseas clinical trials of RC48 according to plan. The main challenges faced in the internationalization process include differences in regulatory environments in different countries and regions, the complexity of market access policies, and the dynamic changes in the competitive environment. The company is actively collaborating closely with Pfizer to provide necessary support and data to facilitate clinical development and application in overseas markets.
3 m ago
STMicroelectronics invests $60 million to upgrade its French factory and build a pilot line for advanced chips.
See all latest
